Effect of Once-daily, Low-dose Pemafibrate Administration in Dyslipidemic Patients with Chronic Kidney Disease Stages G3b and G4

DOI
  • Sakurai Junji
    Department of Pharmacy, Tohoku Medical and Pharmaceutical University Wakabayashi Hospital
  • Ishikawa Taiga
    Division of pathophysiology, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University
  • Sato Shinsuke
    Department of Pharmacy, Tohoku Medical and Pharmaceutical University Wakabayashi Hospital
  • Takahashi Tomoko
    Division of pathophysiology, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University
  • Ojima Fumiyoshi
    Clinical Pharmacy Practice Center, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University
  • Kisara Shigeki
    Department of Clinical Pharmaceutics, School of Pharmaceutical Sciences, Ohu University
  • Miyauchi Yasuo
    Department of Pharmacy, Tohoku Medical and Pharmaceutical University Wakabayashi Hospital
  • Andou Shigeki
    Department of Nephrology, Tohoku Medical and Pharmaceutical University Wakabayashi Hospital

この論文をさがす

抄録

Hyperlipidemia is a risk factor for arteriosclerotic disease. Fibrates have been used as therapeutic drugs for hyperlipidemia. Pemafibrate, a novel fibrate, is a selective peroxisome proliferator-activated receptor α modulator that is prescribed to patients with renal dysfunction owing to its unique metabolism and excretory profiles. However, there is limited information on its use in patients with renal dysfunction, which is a risk factor for adverse events in these patients. This study investigated the effect of administering 0.1 mg of pemafibrate once daily to dyslipidemic patients with chronic kidney disease (CKD) that had progressed to stages G3b or G4. A total of six patients were included in this study and a comparison of clinical laboratory data before and after 12 months of pemafibrate administration was performed. The effects of pemafibrate on triglyceride (TG), aspartate aminotransferase, alanine aminotransferase (ALT), lactate dehydrogenase, creatine kinase, serum creatinine, uric acid, hemoglobin A1c levels, and estimated glomerular filtration rate were examined. Of all the measured parameters, TG and ALT levels decreased over time, but there was no clear effect on the other parameters. These results show that once-daily 0.1 mg pemafibrate can be a potential treatment option for patients with CKD. However, the study needs to be extended to a larger population to validate the findings.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ